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ABSTRACT  
Background: Invasive group A Streptococcal infection (iGAS) is a severe disease, often 
requiring admission to an Intensive Care Unit (ICU). Incidence of iGAS in Sweden has 
markedly increased during the last 30 years. The reason for this is not fully understood. 
Aim: First, to do a survey on local epidemiology, clinical manifestations and treatment for 
iGAS. Second, to investigate whether CRP and S-lactate can be used as early predictors for 
intensive care and death, and if there is a correlation between CRP and S-lactate. 
Method: A retrospective medical record review of adults treated for iGAS at Sahlgrenska 
University Hospital, Gothenburg between 1st January 2008 and 30th of June 2013. Descriptive 
analysis was used for the first aim. For the second we used Fisher’s Exact Test for S-lactate, 
and visualization with boxplot for CRP, as predictive values for ICU and death. Pearson’s 
analysis for correlation was performed correlation between CRP and S-lactate. 
Results: 146 patients (60 female, 86 male, median age 61 years) were identified from medical 
records. Local incidence followed the same trend as the national. Incidence was highest in 
November - May. The main verified underlying focuses were skin and soft tissue (48%) and 
lung (14%). Throat was suspected in only 4 %, and in 14% of the patients focus remained 
unknown. Antibiotics were given both as mono therapy and combined therapy. The most 
common antibiotic treatment before culture was cephalosporins or Penicillin G often 
combined with aminoglycosides. After etiological diagnosis was confirmed, the most used 
antibiotics were Penicillin G, Penicillin V and clindamycin. Twentyeight % of the patients 
(n=41, median age 55 y.) was admitted to ICU, and 49% (n=20) of those had no major 
comorbidity. Over all mortality rate within 1 month after hospital discharge was 12% 
(n=17/146, median age 79 y.). Four of those had no major comorbidity. The total number of 
patients with S-lactate sample taken was 102. Patients with initial S-lactate < 2.0 mmol/l were 
never admitted to ICU, however, 7% of them died.  
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S-lactate 2.0 - 3.9 mmol/l led to ICU in 39% and mortality was 2%. Among patients with  
S-lactate ≥ 4.0 mmol/l, 56% were admitted to ICU and 34% died. CRP was found not to be a 
predictor for intensive care and death. There was no significant correlation between initial 
CRP and S-lactate concentrations. 
Conclusions: We saw a rising trend of iGAS 2008 – 2013, with incidence peaks during 
winter and spring, and the main focuses were soft tissue and lung. Elderly and patients with 
major comorbidities were in the majority, but also young and healthy were affected. Initial S-
lactate, but not CRP concentrations, was a predictor for disease severity.  
Key words: invasive group A Streptococcal infection, intensive care, lactate, CRP, antibiotic 
treatment, mortality, pneumonia. 
BACKGROUND  
Epidemiology  
The bacteria Streptococcus pyogenes, synonym with B-hemolytic group A Streptococcus 
(GAS), causes a wide range of infections, practically only in humans. They vary from 
harmless or moderate as impetigo and pharyngitis, to severe and sometimes life threatening as 
erysipelas with septicemia, necrotizing fasciitis and streptococcal toxic shock syndrome. 
Furthermore, analyses have shown that 12% of children older than five years are healthy 
carriers of GAS, compared to 4% among younger children and adults (1) (2). It is difficult to 
distinguish between healthy carriers and individuals with subclinical infection or GAS carriers 
with a viral infection. This knowledge is important to consider when deciding if antibiotic 
therapy is necessary.  Despite several studies, there is still no consensus how to interpret 
positive tests with clinical findings (3). Other facts to take into account when deciding 
whether therapy is necessary or not, is that individuals with positive rapid-test for GAS but no 
clinical presentation may infect people in their surrounding. 
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Among the many clinical presentations of iGAS, soft tissue infections are common. 
Necrotizing fasciitis and myositis are very severe conditions where the muscular fascia or the 
muscles are affected, and the disease often has a quickly developing course from the first 
symptom to life threatening status with septicemia and sometimes Streptococcal toxic shock 
syndrome. “Pain out of proportion” to local status are typical clinical signs and a wound for 
bacterial entrance is not always identified (4).  
Another clinical entity is Streptococcal toxic shock syndrome (STSS) which may occur 
without soft tissue infection. It was in 1993 defined as a state of hypotension (for adults, 
systolic pressure </= 90 mmHg) together with two or more organs affected. That could 
include kidneys, liver, coagulation, lungs (ARDS, acute respiratory distress syndrome) and 
necrotizing soft tissue (5).  
GAS infection is a transmittable disease but there are no clear-cut epidemic outbreaks. The 
bacteria spread either directly from human to human, indirectly via objects, or as a droplet 
infection. Incubation period is one to three days.  
Complications after GAS infections have changed over time. Rheumatic fever, acute 
glomerulonephritis and puerperal fever are complications used to be associated with GAS 
infections, but are rare in Sweden now days. A common thought is that introduction of 
antibiotics changed the panorama of complications, but the decline started before the 
introduction of penicillin. There are several  theories about the causes (for rheumatic fever i.e. 
nutrition, hygiene, access to medical care, and the degree of crowding in households, 
virulence of bacterial strains) but conclusive knowledge is limited on those circumstances (6)  
Streptococcus pyogenes have several serotypes and can be differed by both T-typing and M-
typing. Those classification systems reflect the presence of different bacterial surface proteins 
and M-type analysis is Swedish laboratories’ standard since 2012. The M protein, which is 
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encoded by the emm gene, is an important virulence factor, and to date around 150 different 
M-types are characterized (7). Serotype prevalence varies over time, between regions and 
countries, and is of interest for epidemiological research on GAS and iGAS worldwide (8-14).  
Figure 1. iGAS incidence in Sweden 1989 – 2015. A rise in incidence of iGAS has been 
notified in Sweden since the mid 80’s. The reason is not fully understood. Data collected from 
folkhalsomyndigheten.se (15) 
 
Since 1st July 2004, reporting invasive group A streptococcal infection is compulsory, 
according to the Communicable Diseases Act (Smittskyddslagen). Both the clinic and the 
laboratory are obliged to report all cases of iGAS (defined as positive culture from a sterile 
compartment) to the Institute for Communicable Diseases (Smittskyddsinstitutet) via 
sminet.se. “Probable STSS” is also obliged to be reported, defined as an image of STSS and 
positive GAS-culture from a non-sterile compartment, e.g. soft tissue. In Sweden a rise in 
incidence of iGAS has been notified since the mid 80’s, and the reason for this is not fully 
understood (15). (Fig 1)
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Prognostic markers to identify patients with the highest risk for severe disease and need of 
intensive care are not well defined. Concentrations of blood lactate and C-reactive protein 
concentrations have been suggested to be such markers in many clinical settings.  
Diagnose 
Various combinations of clinical symptoms, positive culture, positive “rapid strep test” and 
detection of bacterial DNA provide help to diagnose GAS infections. Invasive GAS infection 
is confirmed by positive culture from a sterile compartment such as blood, cerebrospinal fluid 
or joint fluid. Even though there sometimes is no positive culture from a sterile compartment, 
invasive GAS infection is still used in clinical settings as diagnose based on clinical 
symptoms, e.g. patients with erysipelas with severe sepsis or septic shock. 
For definition of severe sepsis and septic shock the following criteria based on the SIRS 
concept was used by clinicians: 
Definitions  
Systemic Inflammatory Response Syndrome (SIRS) is an inflammatory response from the 
immune system, with or without infection. SIRS is defined as 2 or more of the following 4 
criteria:  
§ Body temperature above 38 centigrade or below 36 centigrade 
§ Heart rate above 90 beats/min 
§ Respiratory rate above 20 breaths/min or pCO2 < 4.2 Pka 
§ Leucocyte concentration > 12 mmol/l or < 4 mmol/l or 10% immature cells 
 
Sepsis: 
o SIRS caused by infection 
Severe sepsis: 
o Sepsis and hypo perfusion / organ dysfunction / hypotension. (see definitions below) 
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Septic shock: 
o Severe sepsis with hypotension, that does not respond to proper fluid substitution and 
o Hypo perfusion / organ dysfunction  (see definitions below) 
 
Hypotension: 
v Systolic blood pressure < 90 mmHg or need of vasoactive medication to maintain > 90 
mmHg.  
Hypo perfusion: 
v Base excess  < or = -5 and lactate < 1 mmol/l above the highest normal value.  
 
Organ dysfunction: 
v CNS: acute change in mental status (e.g. confusion) 
v Respiration:  
- pO2 < 7.0 kPa (= sat 86%) or pO2 < 5.6 kPa (= sat 78%) if focus for infection is 
lung.  
- pO2/FiO, < 33 or < 27 if focus for infection is lung. 
v Renal: oliguria, < 0.5 ml/kg/h despite proper volume supply 
v Hepatic: S-bilirubin > 45micromol/l 
v Hematologic: thrombocytes < 100 x 10 *9/l, PK/INR >1,5 or APTT > 60 sec (16) 
 
Treatment  
Healthy carriers of GAS and harmless infections such as impetigo are often left without 
systemic antibiotic treatment. Pharyngitis/tonsillitis and moderate skin- and soft tissue 
infections are treated with oral antibiotics, often with ordinary penicillin. Patients with 
invasive infection need immediate treatment with intravenous antibiotics and often also 
intravenous fluids to avoid or treat shock and organ failure. In some cases intensive care with 
mechanic ventilation and/or dialysis is needed. There are also a few other options described 
below. For patients with necrotizing fasciitis surgery is often lifesaving.  
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Streptococcus pyogenes is a gram-positive cocci, sensitive to several antibiotics.  
1st choice of antibiotics is ordinary Penicillin. For oral treatment that is 
phenoxymethylpenicillin (PcV) and for intravenous treatment benzylpenicillin (PcG). The 
difference between those two is that the PcV-molecule has an oxygen atom making it more 
stable to gastric acid, leading to possible treatment per os (17). PcG is given parenterally and 
therefore results in higher tissue concentrations and more efficient antibacterial effects. Up to 
date, there is no resistance development to Penicillin. Second choice, for instance to patients 
with allergy to penicillin, is usually clindamycin, erythromycin or cephalosporins.  
Clindamycin is 1st choice in case of allergy towards penicillin and/or cephalosporins, but 
otherwise restrictions should be applied, due to risk of developing Clostridium difficile 
infection. In severe infections, though, clindamycin is often added to penicillin since the 
combination has some advantages. Those advantages are related to its mechanism. 
Clindamycin blocks the bacteria’s protein synthesis at a ribosomal level, which is not affected 
by the activity of the bacteria, as for penicillin’s mechanism. In case of larger infectious 
inoculate sometimes GAS enter a phase of lower activity, hence clindamycin might be more 
efficient than penicillin, because the binding protein for penicillin on the bacteria’s surface is 
then down regulated (18). Furthermore, a combination of a beta-lactam antibiotic acting on 
the cell wall and an antibiotic effective on the ribosomal level might be an advantage. 
Clindamycin is not affected by the size of the inoculate, as described above, and also have a 
longer half-life that might contribute (19). 
Intravenous cephalosporins, e.g. cefotaxim, are often prescribed septic patients with unknown 
focus and/or etiology, to cover up for gram-negative bacteria. Oral cephalosporins are also 
used as treatment for mild or moderate streptococcal reinfections, e.g. tonsillitis. 
Erythromycin, and other macrolides, is sometimes recommended for GAS-reinfections. 
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However, in late 90’s and early 00’s GAS showed developing resistance toward 
erythromycin. In contrary, that was connected to certain M/emm-types that were more 
prevalent at the time. Between 2005 and 2012 those serotypes declined, and so did the 
resistance (20). Still, the Medical Product Agency (Läkemedelsverket) recommend that 
macrolides should not be used for GAS infections, due to risk for developing resistance(21). 
Intravenous immunoglobulins (ivIg) are sometimes tried out as additional treatment for the 
severely ill patients, especially those with severe fasciitis and myositis with or without 
streptococcal toxic shock syndrome (22) (23). IvIg wields its effect through several 
mechanisms, including neutralizing super antigens, inhibiting complement activation and 
facilitating opsonizing of bacteria. By adding ivIg the inflammatory cascade is generally 
inhibited (23). Prospective randomized clinical studies are, however, lacking. 
Hyperbaric oxygen therapy (HBO) is also sometimes used as additional treatment, even 
though there are no controlled studies that conclude better survival or less need of surgery. 
HBO leads to vasoconstriction and anti-inflammatory effects leading to less edema, less 
growth of bacteria and blocking of toxins. Furthermore, as a result of HBO, leukocytes kill 
bacteria more effectively (in vitro) and oxygen tension rises in ischemic threatened tissue 
(24). 
Despite quick and adequate access to intensive care, mortality is relatively high among 
patients with severe invasive infection such as necrotizing fasciitis and streptococcal shock 
syndrome. A European study comparing iGAS infections in 11 different countries 2003-2004 
found that the overall mortality within 7 days for iGAS was 19%, necrotizing fasciitis 32 %, 
and for STSS 44%. For patients with necrotizing fasciitis surgery is lifesaving and often 
multiple sessions are needed (25). 
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Implication and aim
iGAS causes severe and fatal infections. The national trend is a rising incidence, that up to 
date hasn’t been explained. The aim of this study was to investigate epidemiological, clinical 
and treatment data on iGAS-patients at the University Hospital of Sahlgrenska in Gothenburg 
January 2008 – June 2013. Some specific question raised were: What are the main focuses for 
invasive infections? Are there any seasonal variations? How high is the mortality? How many 
patients need intensive care? Can we define predictors for patients who require intensive care 
or for whom outcome will be fatal?  
SPECIFIC OBJECTIVES 
First: 
• Survey on age, sex, seasonal variation, co-morbidity, focus for infection, location of 
positive culture, intensive care admission, treatment and survival less than one month 
from hospital discharge. 
Second: 
• Is CRP at arrival to the emergency room a predictor for intensive care and death?  
• Is serum-lactate at arrival to the emergency room a predictor for intensive care and 
death? 
• Is there a correlation between CRP and S-lactate concentrations at arrival to the 
emergency room? 
MATERIAL AND METHODS 
Study population 
Patients older than 18 years of age, treated for iGAS (see definition below) at Sahlgrenska 
University Hospital, Gothenburg between 1st January 2008 and 30th of June 2013. All data 
were retrospectively collected from the patients’ medical record. 
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Definition of iGAS  
Two definitions. 
1. Positive culture from a sterile compartment or 
2. Patients with at least on of the following diagnosis in their medical record, coded by the 
ICD-10 system. 
a) A40.0 Sepsis due to streptococcus, group A or 
b) M72.6 Necrotizing fasciitis, caused by group A streptococcus 
Study design 
We conducted a retrospective medical record review. One person collected all data from the 
patients’ medical record in the data base Melior and software connected to Melior such as 
ELVIS, LabBest and scanned documents, and filed it in an excel document where all patients 
received a code for anonymization. 
STATISTICAL METHODS 
We used the software SPSS for all analyses. Descriptive analyses were used for the first aim. 
For the second we conducted Fisher’s Exact Test for S-lactate as predictor for ICU and death, 
and for CRP the corresponding analysis was chosen to be a simple boxplot. Pearson’s analysis 
was used for calculation of linear correlation between CRP and S-lactate.  
ETHICS 
All patients were coded anonymized. The coding key was kept separate from patient data. 
Permission from the Ethical Committee University of Gothenburg to collect data from the 
medical records was obtained and is attached as Appendix 1. 
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RESULTS 
Patient characteristics 
We identified 146 patients treated for invasive betahemolytic group A streptococci bacteria at 
Sahlgrenska University Hospital between 1st January 2008 and 30th June 2013. Sixty (41%) 
were women and eighty-six (59%) were men. Age varied from 18 to 99 with a median of 61 
years. Ninety-four (64%) patients had any kind of major co-morbidity. Circulatory disease 
was the most prevalent (n=45) followed by diabetes mellitus (n=32) and pulmonary disease 
(n=23). Forty-seven (32%) patients had no co-morbidity reported. (Table 1) 
Table 1. Patient characteristics for all included in this study. Data was collected from 
medical records, after ethical permission. We identified 146 patients treated for invasive 
betahemolytic group A streptococci bacteria at Sahlgrenska University Hospital between 1st 
January 2008 and 30th June 2013. Sixty (41%) were women and eighty-six (59%) were men. 
Age varied from 18 to 99 with a median of 61 years. Ninety-four (64%) patients had any kind 
of major co-morbidity. Circulatory disease was the most prevalent (n=45) followed by 
diabetes mellitus (n=32) and pulmonary disease (n=23). Forty-seven (32%) patients had no 
co-morbidity reported. 
  All patients       (n = 146) 
Admitted to 
Intensive Care 
Unit (n = 41) 
Dead within 1 month 
after hospital discharge 
(n = 17) 
Women 41% (n=60) 29% (n=12) 29% (n=5) 
Men 59% (n=86) 71% (n=29) 71% (n=12) 
Age, median 61 y. (18-99) 55 y. (34-91) 79 y. (41-99) 
No major comorbidity 32% (n=47) 49% (n=20) 24% (n=4) 
Major co-morbidity, any 68% (n=99) 51% (n=21) 76% (n=13) 
Circulatory 31% (n=45) 20% (n=8) 71% (n=12) 
Diabetes 22% (n=32) 10% (n=4) 6% (n=1) 
Pulmonary 16%(n=23) 12% (n=5) 29% (n=5) 
Renal 9% (n=13) 5% (n=2) 12% (n=2) 
Liver 5% (n=8) 5% (n=2) 0% (n=0) 
Malignancy 11% (n=16) 3% (n=1) 12% (n=2) 
Immunosuppression 5% (n=8) 5% (n=2) 6% (n=1) 
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Figure 2. Cases of invasive group A streptococcal infections per year at Sahlgrenska 
University Hospital, January 2008 – June 2013. For 2013 only January – June is reported 
due to the timing of data collection of this study. The numbers represent patients in this study 
identified by either 1. Positive culture from a sterile compartment or 2. At least one of the 
following diagnoses in their medical record. A40.0 Sepsis due to streptococcus, group A or 
M72.6 Necrotizing fasciitis, caused by group A streptococcus. 
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Figure 3. Seasonal variation of invasive group A streptococcal infections at Sahlgrenska 
University Hospital per month, Jan 2008 - June 2013. For 2013 only January – June is 
reported due to the timing of data collection of this study. Month and year was defined by 
which day they attended the clinic. The numbers for each month represent patients identified 
by either 1. Positive culture from a sterile compartment, or 2. All patients were diagnosed 
with either A40.0 Sepsis due to streptococcus, group A or M72.6 Necrotizing fasciitis, caused 
by group A streptococcus. 
 
Figure 4. Seasonal variation of invasive group A streptococcal infection at Sahlgrenska 
University Hospital, January 2008 - June 2013, compiled per month. For 2013 only January 
– June is reported due to the timing of data collection of this study.Month and year was 
defined by which day they attended the clinic. The numbers for each month represent patients 
identified by either 1. Positive culture from a sterile compartment, or 2. Diagnosed with either 
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A40.0 Sepsis due to streptococcus, group A or M72.6 Necrotizing fasciitis, caused by group A 
streptococcus. 
 
Focus of infection 
Some patients had more than one focus of infection, therefor the numbers in Figure 5 doesn’t 
correspond with those described in the text below. 
The most prevalent focus of infection was soft tissue (n=74) (60% of the patients). Two of 
those patients had necrotizing fasciitis. The second most prevalent focus was lung (n=22) 
(15% of the patients) followed by unknown (n=21) (14% of the patients). 
 
Figure 5. Focus of invasive group A streptococcal infection at Sahlgrenska University 
Hospital January 2008-June 2013. For 2013 only January – June is reported due to the 
timing of data collection of this study. Percentage numbers represent the share of infection 
focuses (positive cultures), not percentage of patients. Some patients have more than one 
focus, and therefor the total numbers of infection focuses reported are more than the total 
number of patients. Focuses were identified by “positive culture” in the patients’ medical 
record.
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Figure 6. Positive bacterial cultures from sterile compartments. Data on positive culture 
from sterile compartments were identified in the patients’ medical record. We found 113 
positive cultures in blood (77%), 9 in joint (6%) and 1 in cerebrospinal fluid (1)
In sterile compartments we found 113 positive cultures in blood (77%), 9 in joint (6%) and 1 
in cerebrospinal fluid (1%) (Fig 6). Even if there was no positive culture from any sterile 
compartment in 25 cases (17%) and the invasive infection diagnosis was made on clinical 
grounds, 20 of these patients had positive culture from soft tissue (wound or tissue) 
confirming they suffered from a group A streptococcus infection. The remaining 5 cases, 
lacking positive cultures from sterile compartments have not been further investigated and are 
until now seen as primary sepsis of unknown focus. Totally, soft tissue cultures were positive 
in 53 cases (36%), throat culture in 5 cases (4%) and in 15 cases (10%) there was a positive 
culture from other locals, few and diverse and therefore not presented. 
CRP as predictor of intensive care and death 
The 50% confidence interval of initial CRP was partly overlapping between those who were 
admitted to intensive care unit (ICU) than those who were not. The median CRP value was 
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higher for patients admitted to ICU than for non-ICU patients. The overall highest CRP value 
was slightly higher in the non-ICU group (Fig 7). The 50% confidence interval of initial CRP 
was completely overlapping between those who died within 1 month from hospital discharge 
and those who didn’t. The median CRP value was higher for survivors than for non-survivors. 
The overall highest CRP values were found in the survivors’ group. (Fig 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S-lactate as predictor of intensive care and death 
Among all patients who had a S-lactate registered (n=102) 34% (n=35) were admitted to ICU 
and 14% died within one month. Patients with initial S-lactate <2 mmol/l were never admitted 
to ICU, however, 7% (n=2) in this group died. In the intermediate group (lactate between 2.0-
Figure 8. Comparing initial CRP levels 
of two groups with different outcomes 
according to 1 month mortality  
YES = died within 1 month.  
NO = 1 month survivors.  
The blue box contains 50% of patient 
data. The line on each side of the blue 
boxes, parallel to the y-axis, represents 
the higher and lower 25% of patient 
data. Between the two horizontal lines 
are the total range of CRP-values 
represented. The line across the blue box 
is the median value. 
 
Figure 7. Comparing initial CRP levels 
of two groups with different outcomes 
according to Admission to intensive 
care unit.  
YES = admitted to intensive care unit. 
NO = not admitted to intensive care unit. 
The blue box contains 50% of patient 
data. The line on each side of the blue 
boxes, parallel to the y-axis, represents 
the higher and lower 25% of patient 
data. Between the two horizontal lines 
are the total range of CRP-values 
represented. The line across the blue box 
is the median value. 
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3.9 mmol/l) 39% (n=17) were admitted to ICU and mortality was 2% (n=1). In the high S-
lactate group (lactate above 4.0 mmol/l) significantly more patients 56% (n=18) were 
admitted to ICU and 34% (n=11) died. p < 0.001 for both analysis. (Table 2) 
Table 2. Initial S-lactate concentrations, admission to intensive care unit and mortality. 
Among all patients who had a S-lactate registered (n=102), 34% (n=35) were admitted to 
ICU and 14% died within one month. Patients with initial S-lactate <2 mmol/l were never 
admitted to ICU, however, 7% (n=2) in this group died. In the intermediate group (lactate 
between 2.0-3.9 mmol/l) 39% (n=17) were admitted to ICU and mortality was 2% (n=1). In 
the high S-lactate group (lactate above 4.0 mmol/l) significantly more patients 56% (n=18) 
were admitted to ICU and 34% (n=11) died. 
 
Admission to Mortality within   
Intensive Care Unit 1 month   
 S-lactate (mmol/L) Count Percent Count Percent Total (n) 
< 2.0 0 0% 2 7% 27 
 2.0 – 3.9 17 39% 1 2% 43 
 > 4.0 18 56% 11 34% 32 
Total 35 34% 14 14% 102 
 
Correlation between initial CRP and initial S-lactate 
Spearman’s correlation analysis showed no significant correlation between initial CRP 
concentrations and S-lactate (n=102). Correlation coefficient: 0.131, p > 0.05 (Fig 9) 
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Figure 9. Correlation between initial CRP and initial S-lactate. Spearman’s correlation 
analysis showed no significant correlation between initial CRP concentrations and S-lactate 
(n=102). Correlation coefficient: 0.131, p > 0.05 
 
Antibiotics  
The most frequently used antibiotics, before culture results were known, were cephalosporins 
(n=79) (54%), PcG (n=32) (22%) and aminoglycosides (n=31) (21%) Treatment was given in 
different combinations and sometimes as mono therapy (Fig 10).  
Figure 10. Initial antibiotic treatment, i.e. before receiving the bacterial culture result. 
Patients often received more than one type of antibiotics. The most frequently used initial 
antibiotics were cephalosporins (n=79) (54%), PcG (n=32) (22%) and aminoglycosides 
(n=31) 
(*Benzylpenicillin **Piperacillin/Tazobactam ***Trimetoprim/Sulfametoxazol) 
After culture results were known, PcG was the most frequently used antibiotic (n=76) (48%) 
followed by PcV (n=41) (28%) and clindamycin (n=40) (27%). As for initial antibiotics, after 
culture results were known, treatment was given in different combinations and/or as mono 
therapy (Fig 11). Antibiotic therapy was for some patients shifting more than once after their 
result was known. 
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Figure 11. Antibiotic treatments after bacterial culture results. Patients received more than 
one antibiotic in some cases. After culture results were known, PcG was the most frequently 
used antibiotic (n=76) (48%) followed by PcV (n=41) (28%) and clindamycin (n=40) (27%). 
After culture results were known, treatment was given in different combinations and/or as 
mono therapy. 
* Benzylpenicillin **Phenoxymethylpenicillin ***Antibiotics defined in Figure 10 
****Piperacillin/Tazobactam 
 
Other treatments 
Surgery: Surgery was performed in forty patients (28%), ranging from 1 to 9 sessions with a 
mean of 3 times and a median of 2 times. (Fig 12) 
IVIG: Nineteen patients (13%) received intravenous immunoglobulin, ranging from 1 to 4 
days with a mean of 2.2 and a median of 2 days. Seven patients who were treated with ivIg 
died, and opposite, of those 17 who died 7 got ivIg treatment. All patients, except for one, 
who received ivIg were intensive care unit patients. No data of dosage collected. (Fig 12) 
HBO: Ten patients (7%) received hyperbaric oxygen therapy, ranging from 1 to 6 sessions 
with a mean of 3.5 times and a median of 3.5 times. (Fig 12)
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Figure 12. Number of patients receiving additional treatment beside antibiotics.  
Surgery was performed in forty patients (28%), ranging from 1 to 9 sessions with a mean of 3 
times and a median of 2 times. Nineteen patients (13%) received ivIg*, ranging from 1 to 4 
days with a mean of 2.2 and a median of 2 days. Seven patients who were treated with ivIg* 
died, and opposite, of those 17 who died 7 got ivIg treatment. All patients except for one, who 
received ivIg, were intensive care unit patients. No data of dosage collected. Ten patients 
(7%) received HBO**, ranging from 1 to 6 sessions with a mean of 3.5 times and a median of 
3.5 times. 
*Intravenous immunoglobulin ** Hyperbaric oxygen therapy
Intensive care 
41 patients (28.3%) received intensive care. For 30 patients of those 41, that included 
mechanical ventilation and for 16 patients it included dialysis. (Fig 13)
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Figure 13. Patients admitted to Intensive Care Unit. Forty-one (of 146) patients were 
admitted to Intensive Care Unit (ICU). Thirty of those received mechanical ventilation and 16 
needed dialysis.
Mortality 
17 (12%) of 146 died within 1 month after hospital discharge of whom nine (53%) patients 
did not receive intensive care. 
 
Figure 14 Mortality rate. Seventeen (12%) patients included in this study died within one 
month after hospital discharge of whom nine patients (53%) did not receive intensive care. 
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DISCUSSION 
The increasing number of invasive streptococcal infections during the last 30 years in Sweden 
is worrying and difficult to explain. In our study, a similar tendency of increasing number was 
observed as in the national report and linked to the dark half of the year, with focus of 
infections mainly from the soft tissue although lung focus was surprisingly common. There 
exist several theories explaining the increasing incidence such as new virulent bacterial 
strains, bacterial strains in a  population that lack local immunity, and crowding of children in 
day care center resulting in a large bacterial pool in the society.  
Seasonal variation 
Most infections occurred between November and May, as found in previous studies (25). This 
finding support the crowding theory since it is during this time of the year that most children 
are indoors and closer to each other than during the half-year with better climate. 
Furthermore, the influenza season is concurrent with the high incidence period in our study, 
and, as Barnham clarifies it is already known that “Acute viral tract infections can be 
associated with the occurrence of S. pyogenes pneumonia, reflecting virus-induced epithelial 
damage in the respiratory tract together with transient immune suppression” (26) In 
conclusion, the high and low season for iGAS infections were anticipated since this pattern is 
previously observed and stable since decades ago. 
Focus 
The most prevalent focus of infection was soft tissue, in more than half of the patients. The 
second most prevalent focus was lung followed by unknown. There were only exceptional 
cases with focus from the throat. This distribution is in agreement with previous 
observations(27). 
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Focus – lung  
 A decline in Streptococcus pyogenes community acquired pneumonia has been observed 
since the clinical introduction of penicillin in 1942. Nevertheless, S. pyogenes is a pathogen 
that still causes severe and fatal lung infections, including the 22 patients in our study. A 
recent study showed a high mortality rate (20%) of S. pyogenes pneumonia, with half of the 
patients dying within 24 h after admission (28).  
Surprisingly there have been few studies on S. pyogenes pneumonia more specifically since 
STSS was first described three decades ago. Muller et. al.  published a large population-based  
study 2003(29). They found a higher case fatality rate for GAS pneumonia than for 
necrotizing fasciitis, 38% vs. 26%, high lightening its severity. Furthermore they pointed out 
that the high mortality and rapid progression occurred despite early appropriate antibiotic 
therapy and the use of advanced supportive measures, suggesting that interventions directed at 
the underlying pathogenesis of STSS will be required to improve outcomes. In 2003 
intravenous immunoglobulin had recently been introduced in clinical settings but they had too 
few patients treated with ivIg to draw any conclusions. Still, 13 years later, there are no 
guidelines or sufficient studies on ivIg-treatment. 
Focus - throat 
In our study throat represented 4% of all focuses, which is a small number according to the 
total incidence of GAS throat infections in society. GAS throat infection is not considered a 
common entry for iGAS infections, but Strömberg et al. found 12% of upper respiratory tract 
symptoms among their 97 inward patients with group A Streptococcus bacteremia in a 
Swedish national outbreak 1988 (30).  
Are throat infections truly less invasive to the extent found in this study or are throat 
infections hidden in the rather large group of “Unknown”, which comprises 14% of the total 
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material in our study? Since our study is retrospective it is difficult to know if all clinical data 
has been asked for. One of our theories that might apply is that throat samples for culture or 
rapid test are less performed in infectious patients without an obvious focus at the emergency 
room compared with for example urine culture, reflecting the physician’s lower expectation 
on throat being the focus of severe disease. Also, as Ekelund et al argue in their study from 
2004 (31) where they investigate gastrointestinal symptoms as primary sign of severe invasive 
group A streptococcal infections, throat ache might not be noted at the emergency room due 
to the domination of gastrointestinal symptoms, caused by GAS toxins, or other symptoms. 
Although throat rarely is the origin for severe disease it might transmit bacteria to other 
family members or people of close relations and for instance infect a wound. The Swedish 
national recommendations on handling of pharyngotonsillitis(32) is based on the Centor 
criteria(33), a clinical tool developed to help physicians decide whether to treat 
pharyngotonsillitis with penicillin (or other antibiotics) or not. At least for the last decade, it 
has been an ongoing argumentation against Centor criteria in favor of testing all patients with 
a sored and paining throat with either rapid test or culture, and then treat all patients testing 
positive for GAS. (34-36) 
In this retrospective study it was not possible to analyze if there was any suspected GAS 
pharyngotonsillitis in the environment before the patient developed iGAS,. Since GAS is a 
common bacteria also in milder infections, it would require serotyping of both iGAS 
infections, milder GAS-infections and carriers to clarify the connection between mild and 
invasive infections. 
Treatment 
Antibiotic treatment before etiology was confirmed, was dominated by cephalosporins, given 
in almost 50% of the patients, followed by PcG (22%) and aminoglycosides, often given as a 
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combination with these two. Streptococcus pyogenes is sensitive to both cephalosporins and 
PcG but resistant to aminoglycosides. Since decision on initial antibiotic treatment most often 
is taken on clinical grounds for community acquired septic patients of unknown etiology, it is 
reasonable that aminoglycosides were prescribed along with either cephalosporins or PcG to 
extend the gram-negative spectrum and to use its fast bactericidal effect. 
After culture result was received, antibiotic pattern changed evidently towards narrower 
antibiotics such as PcG , PcV  and clindamycin. Aminoglycosides and cephalosporins were 
now given only rarely. Some patients were still treated with a combination of antibiotics after 
culture, most commonly penicillin and clindamycin to use the different action of killing the 
bacteria, but also sometimes with meropenem that doubled from 3.5% to 7% of unknown 
reason. 
Mortality 
17 patients (12%) died within one month from hospital discharge. Nine of those received 
intensive care and eight did not receive intensive care. Looking closer into data on deceased 
patients, it was clear that the non-intensive care group had severe co-morbidities and high age 
and probably it was for ethical reasons they weren’t provided intensive care. However, these 
facts affect all analyses in this study concerning intensive care and mortality.  
CRP and S-lactate as predictors for intensive care and death 
S-lactate, but not CRP concentrations, was a good predictor for disease severity.  
For S-lactate it was clear that if you had an initial value < 2 mmol/l you would not qualify for 
intensive care during the present period of disease. But two patients in this subgroup died 
within 1 month. Those two had three and four major comorbidities respectively. Hence, it 
falls in line with the reasoning above that some patient are very frail to begin with, having 
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limited chances to survive severe disease, even though their S-lactate levels were moderate in 
this case. 
In the intermediate group, with S-lactate 2.0 – 3.9 mmol/l, 39% were admitted to intensive 
care unit and 2% died, saying that many in this interval required advanced interventions, and 
could also benefit from them. 
In the high S-lactate group, S-lactate ≥ 4 mmol/l, there was a difference from the intermediate 
group primary according to mortality, with 34% in the high lactate group and 2% in the 
intermediate. This suggests that an intermediate S-level predicts benefit from intensive care in 
case you need it, whereas if you have a high lactate and need intensive care chances for a 
fortunate outcome is clearly lower, but no conclusions can be drawn from these comparison 
although they were significant with p < 0.001 for both ICU admission and mortality. 
Mikkelsen et. al. 2009 published a study on S-lactate’s potential predictive value for 28-day 
mortality and found that initial serum lactate was associated with mortality independent of 
organ dysfunction in this study of emergency department patients with severe sepsis. 
Furthermore, they demonstrated that the relationship between serum lactate levels and 
mortality was independent of the presence of clinically apparent shock. Therefore, serum 
lactate, in its association with mortality, did not seem to function solely as a marker of 
clinically apparent organ dysfunction or hypotension. (37, 38). 
They also conducted a retrospective medical record review over septic patients at the 
emergency department, with all its strengths and limitations. For their statistic analyses they 
used logistic regression, that we also aimed to do, but since we didn’t have sufficient patients 
in each group we failed, and had to shift to another method, the Fisher’s Exact Test. Hence, 
the results are not as easy to compare as if we could have used logistic regression. Their 
question was also partly another since they compared patients with and without shock. 
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Despite those differences, some comparisons can be made. For example, they found that both 
intermediate and high serum S-lactate were predictive for 28-day mortality, but our results 
showed higher mortality only for high lactate patients. Another difference is that we had two 
patients in the low lactate group who died, whereas all their low lactate patients survived. Our 
results should be analyzed with some caution due to limited data, and more research should be 
done. (37) (Of additional interest is that only 109/147 had a S-lactate result in our records, 
suggesting S-lactate can be taken on wider indications) We agree with previous previous 
studies that a single serum lactate measurement provides useful information in patients with 
severe sepsis . 
It is well known that CRP > 5 is a good marker for inflammation, often with infectious 
etiology. To estimate the infection’s severity though, CRP is of little help. It can even be a 
severe mistake trying to interpret the infection’s severity based on CRP concentrations, as 
shown in our study. Since CRP mirrors the level of inflammation 24 hours ago and iGAS 
infections often develop very quickly, our results underline how important it is to follow the 
patient both clinically and with new laboratory analyses. 
There was no correlation between CRP and S-lactate at arrival for patients in our study. Since 
we have concluded that initial S-lactate can be useful as predictor for disease severity and 
CRP is not an appropriate predictor for disease severity, it is reasonable that there was no 
correlation between those two markers. 
The role of serotype for disease severity 
It has been debated why iGAS incidence increases. Many scientists investigate whether 
certain surface serotypes seem to comprise a greater virulence factor than others (8, 12, 17, 
25, 39-42). Rogers et al also compare serotype incidence among severe infections with 
incidence of serotypes among mild infections and also with prevalence of carriers in the 
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community. They found that strain serotype prevalence, is the major factor responsible for an 
increase in serious group A streptococcus infections(13). Thy argue that the same serotype 
that causes many invasive infections also causes many mild infections and it is at the same 
time widely spread among carriers (13, 43). It would have been interesting to explore the local 
epidemiological circumstances on serotypes, but we had no possibility to look further into 
that, since the laboratory connected to Sahlgrenska University Hospital shifted from T-typing 
to M-typing during the period of our study, and as of equal importance, we had no control 
groups for M-typing from neither mild infections nor carriers. 
Strengths and weaknesses 
Strengths with the study are that there is only one major hospital in the area making the 
patient material representative for the population and that all medical charts were entered and 
analyzed by the same person. We also had a fairly long follow up time. A weakness with the 
study is the retrospective approach. Medical records are sometimes vague and important data 
is missing. Patient history may miss the question about throat symptoms and if there were any 
GAS infections in the environment. Mortality and need of intensive care is sometimes more 
dependent on concomitant diseases than the iGAS infection. Furthermore, we were not able to 
analyze the serotypes.  
CONCLUSIONS AND IMPLICATIONS 
We saw a rising trend of iGAS 2008 – 2013, with incidence peaks during winter and spring, 
and the main focuses were soft tissue and lung. Initial S-lactate, but not CRP concentrations, 
was a good predictor for disease severity. Elderly and patients with major comorbidities were 
in the majority, but also young and healthy was affected among both severe and fatal cases. 
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Further research 
There is a high severity rate of iGAS pneumonia and a low number of studies addressing that 
problem. It would be of interest and importance to look deeper in to the circumstances around 
the 22 pneumonia patients in this study, such as mortality, co-morbidity, development of 
disease, admission to intensive care and treatment. It would also be interesting to look closer 
into the soft-tissue infected patients data since they are the largest subgroup of patients. The 
fact that 40 patients received surgery but only 2 got necrotizing fasciitis diagnose raise i.e. the 
question whether necrotizing fasciitis is under diagnosed or not. Therefore surgical patients is 
another subgroup worth having a closer look upon.  
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Allvarliga infektioner med streptokocker grupp A i Göteborg 2008 - 2013 
Grupp A streptokocker (GAS) är en för människa sjukdomsorsakande bakterie som kan leda 
till infektioner i olika delar av kroppen och av olika svårighetsgrad. Exempel på lindrig 
infektion är svinkoppor, medelsvåra kan vara halsfluss, svåra kan vara rosfeber och mycket 
svåra kan vara lunginflammation eller muskelinfektion som även kan bli livshotande. När 
tidningarna skriver om ”mördarbakterien” eller ”den köttätande bakterien” är det oftast grupp 
A streptokocker det handlar om. De svåraste tillstånden inträffar när bakterien blir invasiv, 
vilket innebär att den tar sig till en lokal i kroppen som vanligtvis är helt steril, dvs. fri från 
bakterier. Den har då oftast tagit sig till blodet, men det kan även vara ledvätska eller 
ryggmärgsvätska. 
Under senare år har antalet fall av allvarliga streptokock-infektioner ökat vilket motiverar 
denna tillbakablickande journalstudie på patienter med invasiv GAS-infektion. Man kan kalla 
det för en kartläggning av grundläggande data att ha som utgångspunkt för vidare 
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frågeställningar och forskning. Ålder (alla är över 18 år), kön, bakomliggande sjukdomar, 
infektionsfokus, ev. intensivvård, behandling inkl. antibiotikaval, laboratoriedata vid 
inläggning är sådant som jag har studerat. Tidsperioden är januari 2008 – juni 2013 och 
upptagningsområdet är Sahlgrenskas alla sjukhus i Göteborg. 
Undersökningen visade att av146 patienter så var 60 kvinnor och 86 män och medianåldern 
var 61 år. Ökningen man har sett i Sverige motsvaras av samma slags variation i Göteborg. 
Högsäsong för allvarliga GAS-infektioner låg mellan november och maj vilket är vanligt 
sannolikt för att både vuxna och barn vistas mera inomhus då, och då sprids bakterien lättare 
mellan människor. Att det är influensasäsong drabbar vissa särskilt hårt då de kan få först en 
influensainfektion och strax därefter en iGAS-infektion för att luftvägarna är skadade och 
immunförsvaret nedsatt. Nära 50% hade sin sjukdom i hud eller mjukdelar, men även 
lunginflammation var vanligt (14%). I lika många fall hittade man inte var infektionen hade 
sitt ursprung.  
När patienterna kom in till sjukhus fick de antibiotika som är bra mot flera sorters bakterier, 
och sedan när man genom odling fått reda på vilken bakterie som orsakat sjukdomen bytte 
man ofta till mer specifika sorter. De flesta som blir allvarligt sjuka av invasiv GAS-infektion 
har en eller flera sjukdomar i botten, men även unga och friska kan drabbas hårt. Fyrtioen 
patienter behövde vårdas på intensiven och 20 av dessa var friska sedan tidigare. Inom en 
månad efter utskrivning var det 17 patienter som dog, och fyra av dem var tidigare friska.  
För att se om man har en infektion i kroppen är det vanligt att ta ett prov som heter CRP, eller 
snabbsänka som det ibland också kallas. Vi kunde bekräfta att det är ett prov som är bra på att 
påvisa infektionssjukdom, men som är dåligt på att säga hur allvarligt sjuk man är eller 
kommer att bli. Ett annat prov man kan ta är laktat, eller mjölksyrekoncentration, i blodet. Det 
är ett mycket bättre prov att använda när man försöker bedöma hur allvarligt sjuk en patient är 
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eller kommer att bli. Vid låga värden kan man känna sig trygg, men vid högre värden är det 
stor risk att man kommer behöva intensivvård och att man kanske kommer dö pga sjukdomen. 
Det är alltså av värde att ta ett laktatprov för att kunna sätta in behandling tidigt i 
sjukdomsförloppet för att utgången ska bli så bra som möjligt.  
Mer forskning behövs på många områden när det gäller grupp A streptokocker, men vi vill 
särskilt lyfta fram behovet av forskning om lunginflammationer orsakade av GAS, mera 
forskning kring laktatets möjligheter att fungera som tidig varningssignal samt forskning 
kring ytterligare behandling vid sidan av antibiotika och intravenöst vätska, eftersom många 
blir svårt sjuka och dör trots att de tidigt får rätt sorts behandling.  
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